SEARCH

SEARCH BY CITATION

References

  • 1
    Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80: 82741.
  • 2
    Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 2001; 23: 57989.
  • 3
    Shirasaka T, Shimamato Y, Ohshimo H et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7: 54857.
  • 4
    Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho 2001; 28: 138190.
  • 5
    Fujii M, Tomita K, Nishijima W et al. Phase I/II Study of S-1 plus Cisplatin Combination Chemotherapy in Patients with Advanced/Recurrent Head and Neck Cancer. Jpn J Clin Oncol 2010; 40: 21421.
  • 6
    Harada K, Kawaguchi S, Supriatno, Onoue T, Yoshida H, Sato M. Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol 2004; 40: 7139.
  • 7
    Fukushima M, Sakamoto K, Sakata M, Nakagawa F, Saito H, Sakata Y. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo. Oncol Rep 2010; 24: 130713.
  • 8
    Fukushima M, Ohshita H, Taguchi T Combined therapy with radiation and S-1, an oral new 5FU prodrug, is markedly effective against non-small cell lung cancer xenografts in mice. Eur J Cancer 2005; Supplements 3: 343.
  • 9
    Matsushima E, Yoshida K, Kitamura R. Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 1997; 691: 95104.
  • 10
    Hirata K, Horikoshi N, Aiba K et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999; 5: 20005.
  • 11
    Nakamura K, Tahara M, Kiyota N et al. Phase II trial of concurrent chemoradiotherapy with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck: Japan Clinical Oncology Group Study (JCOG0706). Jpn J Clin Oncol 2009; 39: 4603.
  • 12
    Ajani JA, Rodriguez W, Bodoky G et al. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. 2009 ASCO Annual Meeting. Orlando, FL: Supplement to Journal of Clinical Oncology, 2009; 204s (abstract 4511).
  • 13
    Milano G, Roman P, Khater R, Frenay M, Renee N, Namer M. Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. Int J Cancer 1988; 41: 53741.
  • 14
    Gamelin EC, Danquechin-Dorval EM, Dumesnil YF et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996; 77: 44151.
  • 15
    Hillcoat BL, McCulloch PB, Figueredo AT, Ehsan MH, Rosenfeld JM. Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer 1978; 38: 71924.
  • 16
    Konno H, Tanaka T, Baba M et al. Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) on liver metastasis of xenotransplanted human colon carcinoma. Jpn J Cancer Res 1999; 90: 44853.
  • 17
    van Groeningen CJ, Peters GJ, Schornagel JH et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000; 18: 27729.
  • 18
    Cohen SJ, Leichman CG, Yeslow G et al. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin Cancer Res 2002; 8: 211622.
  • 19
    McLaughlin BT, Gokhale AS, Shuai Y et al. Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: The University of Pittsburgh experience. Laryngoscope 2010; 120: 715.
  • 20
    van der Weide J, Steijns LS Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem 1999; 36 (Pt 6): 7229.
  • 21
    Yoshida R, Nakajima M, Nishimura K, Tokudome S, Kwon JT, Yokoi T. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 2003; 74: 6976.
  • 22
    Daigo S, Takahashi Y, Fujieda M et al. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 2002; 12: 299306.
  • 23
    Ikeda K, Yoshisue K, Matsushima E et al. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res 2000; 6: 440915.
  • 24
    Ajani JA, Faust J, Ikeda K et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 2005; 23: 695765.